SPI Premium Insight: Optum’s Date With Destiny as EMIS Acquisition Decision Looms

Published: March 23, 2023

By tomorrow, Optum Health must respond to the UK’s Competition and Markets Authority (CMA) objections over its planned acquisition of EMIS. If approved, the £1.24B ($1.52B) deal for the UK’s leading primary care EHR vendor promises to have wide-reaching implications for the NHS.  

The Signify View 

The CMA’s principal objections to the acquisition, announced last June, revolve around its potential impact on the competitive landscape of the UK’s drug Clinical Decision Support (CDS) and population health management (PHM) markets. 

Already have an account? Sign in here